Metabolomics in cancer biomarker discovery: Current trends and future perspectives

Journal of Pharmaceutical and Biomedical Analysis

Volumn 87, Issue , 2014, Pages 1-11

  Armitage, Emily G ^a   Barbas, Coral ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Biological samples; Biomarker; Cancer; Fingerprinting; Metabolomics

Indexed keywords

ACETYLCARNITINE; ALANINE; ARACHIDONIC ACID; BUTYRIC ACID; CARNITINE; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; GLYCOPROTEIN; HISTIDINE; HYDROXYBUTYRIC ACID; HYPOXANTHINE; LINOLEIC ACID; LONG CHAIN FATTY ACID; LYSINE; LYSOPHOSPHATIDYLCHOLINE; METHIONINE; PALMITIC ACID; PHENYLALANINE; PHOSPHORYLCHOLINE; SARCOSINE; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; STEARIC ACID; TAUROCHENODEOXYCHOLIC ACID; TRIGONELLINE; TRYPTOPHAN; TUMOR MARKER; TYROSINE; UNINDEXED DRUG; VALINE;

BLADDER CANCER; BREAST CANCER; CITRIC ACID CYCLE; COLORECTAL CANCER; ESOPHAGUS CANCER; GLYCOLYSIS; HUMAN; KIDNEY CANCER; LIQUID CHROMATOGRAPHY; LIVER CANCER; LUNG CANCER; METABOLOMICS; MOUTH CANCER; OVARY CANCER; PANCREAS CANCER; PENTOSE PHOSPHATE CYCLE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; REDOX STRESS; REVIEW; STOMACH CANCER; TANDEM MASS SPECTROMETRY;

BIOLOGICAL SAMPLES; BIOMARKER; CANCER; FINGERPRINTING; METABOLOMICS;

BIOMEDICAL RESEARCH; HUMANS; METABOLOMICS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889591862     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.08.041     Document Type: Review

References (100)

1. Bianco R.B., Melisi D., Ciardiello F., Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. European Journal of Cancer 2006, 42:290-294.
2. Mathon N.E., Lloyd A.C. Cell senescence and cancer. Nature Reviews Cancer 2001, 1:203-213.
3. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Dunn W.B. Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes. Physical Biology 2008, 5:11001.
5. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Research 2006, 66:8927-8930.
6. Pedersen P.L. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the Warburg Effect, i.e., elevated glycolysis in the presence of oxygen. Journal of Bioenergetics and Biomembranes 2007, 39:211-222.
7. Diaz-Ruiz R., Uribe-Carvajal S., Devin A., Rigoulet M. Tumor cell energy metabolism and its common features with yeast metabolism. Biochimica et Biophysica Acta 2009, 1796:252-265.
8. Warburg O. Origin of cancer cells. Science 1956, 123:309-314.
9. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:U230-U274.
10. Czernin J., Phelps M.E. Positron emission tomography scanning: current and future applications. Annual Review of Medicine 2002, 53:89-112.
11. Buszewski B., Rudnicka J., Ligor T., Walczak M., Jezierski T., Amann A. Analytical and unconventional methods of cancer detection using odor. TRAC Trends in Analytical Chemistry 2012, 38:1-12.
12. Blekherman G., Laubenbacher R., Cortes D.F., Mendes P., Torti F.M., Akman S., Torti S.V., Shulaev V. Bioinformatics tools for cancer metabolomics. Metabolomics 2011, 7:329-343.
13. Teichert F., Verschoyle R.D., Greaves P., Edwards R.E., Teahan O., Jones D.J.L., Wilson I.D., Farmer P.B., Steward W.P., Gant T.W., Gescher A.J., Keun H.C. Metabolic profiling of Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) tissue by H-1-NMR analysis: evidence for unusual phospholipid metabolism. Prostate 2008, 68:1035-1047.
14. Zhang L., Jin H.F., Guo X.G., Yang Z., Zhao L., Tang S.H., Mo P., Wu K.C., Nie Y.Z., Pan Y.L., Fan D.M. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by H-1 nuclear magnetic resonance-based metabonomic profiles. Clinical Biochemistry 2012, 45:1064-1069.
15. Zhang J., Wei S., Liu L., Gowda G.A.N., Bonney P., Stewart J., Knapp D.W., Raftery D. NMR-based metabolomics study of canine bladder cancer. Biochimica et Biophysica Acta-Molecular Basis of Disease 2012, 1822:1807-1814.
16. Li F., Qin X.Z., Chen H.Q., Qiu L., Guo Y.M., Liu H., Chen G.Q., Song G.G., Wang X.D., Li F.J., Guo S., Wang B.H., Li Z.L. Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Communications in Mass Spectrometry 2013, 27:24-34.
17. Leichtle A.B., Nuoffer J.M., Ceglarek U., Kase J., Conrad T., Witzigmann H., Thiery J., Fiedler G.M. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012, 8:643-653.
18. Ganti S., Taylor S.L., Abu Aboud O., Yang J., Evans C., Osier M.V., Alexander D.C., Kim K., Weiss R.H. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Research 2012, 72:3471-3479.
19. Lin L., Yu Q.A., Yan X.M., Hang W., Zheng J.X., Xing J.C., Huang B.L. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst 2010, 135:2970-2978.
20. Lv W.W., Yang T.S. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clinical Biochemistry 2012, 45:127-133.
21. Arlt W., Biehl M., Taylor A.E., Hahner S., Libe R., Hughes B.A., Schneider P., Smith D.J., Stiekema H., Krone N., Porfiri E., Opocher G., Bertherat J., Mantero F., Allolio B., Terzolo M., Nightingale P., Shackleton C.H.L., Bertagna X., Fassnacht M., Stewart P.M. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. Journal of Clinical Endocrinology & Metabolism 2011, 96:3775-3784.
22. Kondo Y., Nishiumi S., Shinohara M., Hatano N., Ikeda A., Yoshie T., Kobayashi T., Shiomi Y., Irino Y., Takenawa T., Azuma T., Yoshida M. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomarkers in Medicine 2011, 5:451-460.
23. Wu H., Xue R.Y., Lu C.L., Deng C.H., Liu T.T., Zeng H.Z., Wang Q., Shen X.Z. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Journal of Chromatography B 2009, 877:3111-3117.
24. Sasada S., Miyata Y., Tsutani Y., Tsuyama N., Masujima T., Hihara J., Okada M. Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. Oncology Reports 2013, 29:925-931.
25. Zhang T., Wu X., Ke C., Yin M., Li Z., Fan L., Zhang W., Zhang H., Zhao F., Zhou X., Lou G., Li K. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. Journal of Proteome Research 2013, 12:505-512.
26. Xiao J.F., Varghese R.S., Zhou B., Ranjbar M.R.N., Zhao Y., Tsai T.H., Di Poto C., Wang J., Goerlitz D., Luo Y., Cheema A.K., Sarhan N., Soliman H., Tadesse M.G., Ziada D.H., Ressom H.W. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. Journal of Proteome Research 2012, 11:5914-5923.
27. Chen J., Zhou L.N., Zhang X.Y., Lu X., Cao R., Xu C.J., Xu G.W. Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: differential metabolite discovery specific to ovarian cancer. Electrophoresis 2012, 33:3361-3369.
28. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6:78-95.
29. Chen J.L., Fan J., Yan L.S., Guo H.Q., Xiong J.J., Ren Y., Hu J.D. Urine metabolite profiling of human colorectal cancer by capillary electrophoresis mass spectrometry based on MRB. Gastroenterology Research and Practice 2012, 2012.
30. Ibanez C., Simo C., Garcia-Canas V., Gomez-Martinez A., Ferragut J.A., Cifuentes A. CE/LC-MS multiplatform for broad metabolomic analysis of dietary polyphenols effect on colon cancer cells proliferation. Electrophoresis 2012, 33:2328-2336.
31. Dumas M.E., Maibaum E.C., Teague C., Ueshima H., Zhou B.F., Lindon J.C., Nicholson J.K., Stamler J., Elliott P., Chan Q., Holmes E. Assessment of analytical reproducibility of H-1 NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP study. Analytical Chemistry 2006, 78:2199-2208.
32. Van Q.N., Veenstra T.D. How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Medicine 2009, 1:5.
33. Halket J.M., Waterman D., Przyborowska A.M., Patel R.K.P., Fraser P.D., Bramley P.M. Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. Journal of Experimental Botany 2005, 56:219-243.
34. Kouremenos K.A., Johansson M., Marriott P.J. Advances in gas chromatographic methods for the identification of biomarkers in cancer. Journal of Cancer 2012, 3:404-420.
35. Garcia A., Barbas C. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics. Methods in Molecular Biology (Clifton, NJ) 2011, 708:191-204.
36. Celebier M., Ibanez C., Simo C., Cifuentes A. A foodomics approach: CE-MS for comparative metabolomics of colon cancer cells treated with dietary polyphenols. Methods in Molecular Biology (Clifton, NJ) 2012, 869:185-195.
37. Ramautar R., Somsen G.W., de Jong G.J. CE-MS for metabolomics: developments and applications in the period 2010-2012. Electrophoresis 2013, 34:86-98.
38. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrometry Reviews 2007, 26:51-78.
39. Teng Q., Huang W., Collette T., Ekman D., Tan C. A direct cell quenching method for cell-culture based metabolomics. Metabolomics 2009, 5:199-208.
40. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 2001, 93:266-276.
41. Ruan K., Song G., Ouyang G.L. Role of hypoxia in the hallmarks of human cancer. Journal of Cellular Biochemistry 2009, 107:1053-1062.
42. Ye J., Mancuso A., Tong X., Ward P.S., Fan J., Rabinowitz J.D., Thompson C.B. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 2011, 109:6904-6909.
43. Cascante M., Benito A., Zanuy M., Vizan P., Marin S., de Atauri P. Metabolic network adaptations in cancer as targets for novel therapies. Biochemical Society Transactions 2010, 38:1302-1306.
44. Yang C., Richardson A., Osterman A., Smith J. Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling. Metabolomics 2008, 4:13-29.
45. Frezza C., Zheng L., Folger O., Rajagopalan K.N., MacKenzie E.D., Jerby L., Micaroni M., Chaneton B., Adam J., Hedley A., Kalna G., Tomlinson I.P.M., Pollard P.J., Watson D.G., Deberardinis R.J., Shlomi T., Ruppin E., Gottlieb E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011, 477:225-228.
46. Tomlinson I.P.M., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E.M., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., Roylance R.R., Olpin S., Bevan S., Barker K., Hearle N., Houlston R.S., Kiuru M., Lehtonen R., Karhu A., Vilkki S., Laiho P., Eklund C., Vierimaa O., Aittomaki K., Hietala M., Sistonen P., Paetau A., Salovaara R., Herva R., Launonen V., Aaltonen L.A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genetics 2002, 30:406-410.
47. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., Ratcliffe P.J., Linehan W.M., Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
48. Cheng Y., Xie G., Chen T., Qiu Y., Zou X., Zheng M., Tan B., Feng B., Dong T., He P., Zhao L., Zhao A., Xu L.X., Zhang Y., Jia W. Distinct urinary metabolic profile of human colorectal cancer. Journal of Proteome Research 2012, 11:1354-1363.
49. Ritchie S.A., Ahiahonu P.W.K., Jayasinghe D., Heath D., Liu J., Lu Y., Jin W., Kavianpour A., Yamazaki Y., Khan A.M., Hossain M., Su-Myat K.K., Wood P.L., Krenitsky K., Takemasa I., Miyake M., Sekimoto M., Monden M., Matsubara H., Nomura F., Goodenowe D.B. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Medicine 2010, 8.
50. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., Ni Y., Zhao A., Xu L.X., Cai S., Jia W. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. Journal of Proteome Research 2009, 8:4844-4850.
51. Qiu Y., Cai G., Su M., Chen T., Liu Y., Xu Y., Ni Y., Zhao A., Cai S., Xu L.X., Jia W. Urinary metabonomic study on colorectal cancer. Journal of Proteome Research 2010, 9:1627-1634.
52. Chan E.C.Y., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., Cavill R., Nicholson J.K., Keun H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). Journal of Proteome Research 2009, 8:352-361.
53. Jordan N.F., Black K., Robey I.F., Runquist M., Powis G., Gillies R.J. Metabolite changes in HT-29 xenograft tumors following HIF-1 alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR in Biomedicine 2005, 18:430-439.
54. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003, 3:721-732.
55. Griffiths J.R., McSheehy P.M.J., Robinson S.P., Troy H., Chung Y.L., Leek R.D., Williams K.J., Stratford I.J., Harris A.L., Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1 beta (HIF-1 beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Research 2002, 62:688-695.
56. Semenza G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Seminars in Cancer Biology 2009, 19:12-16.
57. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Current Opinion in Genetics & Development 2010, 20:51-56.
58. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., Kinoshita T., Saito N., Ochiai A., Tomita M., Esumi H., Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Research 2009, 69:4918-4925.
59. OuYang D., Xu J., Huang H., Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using H-1 NMR spectroscopy and principal component analysis. Applied Biochemistry and Biotechnology 2011, 165:148-154.
60. Urayama S., Zou W., Brooks K., Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Communications in Mass Spectrometry 2010, 24:613-620.
61. Wu H., Xue R., Tang Z., Deng C., Liu T., Zeng H., Sun Y., Shen X. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Analytical and Bioanalytical Chemistry 2010, 396:1385-1395.
62. Wu H., Xue R., Dong L., Liu T., Deng C., Zeng H., Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Analytica Chimica Acta 2009, 648:98-104.
63. Ressom H.W., Xiao J.F., Tuli L., Varghese R.S., Zhou B., Tsai T.-H., Ranjbar M.R.N., Zhao Y., Wang J., Di Poto C., Cheema A.K., Tadesse M.G., Goldman R., Shetty K. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica Chimica Acta 2012, 743:90-100.
64. Gandy K.A.O., Obeid L.M. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 2013, 1831:157-166.
65. Bougnoux P., Hajjaji N., Couet C. The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer. Prostaglandinsi Leukotrienes and Essential Fatty Acids 2008, 79:93-96.
66. Ong K.R., Sims A.H., Harvie M., Chapman M., Dunn W.B., Broadhurst D., Goodacre R., Wilson M., Thomas N., Clarke R.B., Howell A. Biomarkers of dietary energy restriction in women at increased risk of breast cancer. Cancer Prevention Research 2009, 2:720-731.
67. Luisa Doria M., Cotrim Z., Macedo B., Simoes C., Dominguesi P., Helgueroi L., Rosario Domingues M. Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells. Breast Cancer Research and Treatment 2012, 133:635-648.
68. Nam H., Chung B.C., Kim Y., Lee K., Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 2009, 25:3151-3157.
69. Zhang T., Wu X., Yin M., Fan L., Zhang H., Zhao F., Zhang W., Ke C., Zhang G., Hou Y., Zhou X., Lou G., Li K. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clinica Chimica Acta 2012, 413:861-868.
70. Fong M.Y., McDunn J., Kakar S.S. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. Plos One 2011, 6.
71. Woo H.M., Kim K.M., Choii M.H., Jung B.H., Lee J., Kong G., Nam S.J., Kim S., Baii S.W., Chung B.C. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clinica Chimica Acta 2009, 400:63-69.
72. Lin L., Huang Z., Gao Y., Chen Y., Hang W., Xing J., Yan X. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery. Proteomics 2012, 12:2238-2246.
73. Huang Z., Lin L., Gao Y., Chen Y., Yan X., Xing J., Hang W. Molecular & bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Cellular Proteomics 2011, 10.
74. Ganti S., Taylor S.L., Kim K., Hoppeli C.L., Guo L., Yang J., Evans C., Weiss R.H. Urinary acylcarnitines are altered in human kidney cancer. International Journal of Cancer 2012, 130:2791-2800.
75. Kim K., Aronov P., Zakharkin S.O., Anderson D., Perroud B., Thompson I.M., Weiss R.H. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Molecular & Cellular Proteomics 2009, 8:558-570.
76. Lin L., Huang Z., Gao Y., Yan X., Xing J., Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. Journal of Proteome Research 2011, 10:1396-1405.
77. Soliman L.C., Hui Y., Hewavitharanai A.K., Chen D.D.Y. Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. Journal of Chromatography A 2012, 1267:162-169.
78. Thysell E., Surowiec I., Hornberg E., Crnalic S., Widmark A., Johansson A.I., Stattin P., Berghi A., Moritz T., Anttii H., Wikstro P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. Plos One 2010, 5.
79. Zhang J., Bowers J., Liu L., Wei S., Gowda G.A.N., Hammoud Z., Raftery D. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. Plos One 2012, 7.
80. Guo Y., Wang X., Qiu L., Qin X., Liu H., Wang Y., Li F., Wang X., Chen G., Song G., Li F., Guo S., Li Z. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clinica Chimica Acta 2012, 414:135-141.
81. Zhao X., Wang W., Wang J., Yang J., Xui G. Urinary profiling investigation of metabolites with cis-diol structure from cancer patients based on UPLC-MS and HPLC-MS as well as multivariate statistical analysis. Journal of Separation Science 2006, 29:2444-2451.
82. Waszczuk-Jankowska M., Markuszewski M.J., Markuszewski M., Kaliszan R. Comparison of RP-HPLC columns used for determination of nucleoside metabolic patterns in urine of cancer patients. Bioanalysis 2012, 4:1185-1194.
83. Szymanskai E., Markuszewski M.J., Markuszewski M., Kaliszan R. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 2010, 53:1305-1312.
84. Struck W., Siluk D., Yumba-Mpanga A., Markuszewski M., Kaliszan R., Markuszewski M.J. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers. Journal of Chromatography A 2013.
85. Hecht S.S. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002, 23:907-922.
86. Bellance N., Pabst L., Allen G., Rossignol R., Nagrath D. Oncosecretomics coupled to bioenergetics identifies alpha-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes. Biochimica et Biophysica Acta-Bioenergetics 2012, 1817:2060-2071.
87. Nishiumiii S., Kobayashi T., Ikeda A., Yoshie T., Kibi M., Izumi Y., Okuno T., Hayashi N., Kawano S., Takenawa T., Azuma T., Yoshida M. A novel serum metabolomics-based diagnostic approach for colorectal cancer. Plos One 2012, 7.
88. Sava A.C., Martinez-Bisbal M.C., Van Huffeli S., Cerda J.M., Sima D.M., Celdai B. Ex vivo high resolution magic angle spinning metabolic profiles describe intratumoral histopathological tissue properties in adult human gliomas. Magnetic Resonance in Medicine 2011, 65:320-328.
89. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J.D., Laxmani B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X.H., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
90. Kind T., Tolstikovi V., Fiehn O., Weiss R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Analytical Biochemistry 2007, 363:185-195.
91. Dunn W.B., Broadhurst D., Begley P., Zelena E., Francis-McIntyre S., Anderson N., Brown M., Knowles J.D., Halsall A., Haselden J.N., Nicholls A.W., Wilson I.D., Kell D.B., Goodacre R. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols 2011, 6:1060-1083.
92. Kenny L.C., Broadhurst D.I., Dunn W., Brown M., North R.A., McCowani L., Roberts C., Cooper G.J.S., Kell D.B., Baker P.N. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010, 56:741-749.
93. Dunn W.B., Broadhurst D., Ellis D.I., Brown M., Halsall A., O'Hagan S., Spasic I., Tseng A., Kell D.B. A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols. International Journal of Epidemiology 2008, 37:23-30.
94. Kell D.B., Brown M., Davey H.M., Dunn W.B., Spasic I., Oliver S.G. Metabolic footprinting and systems biology: the medium is the message. Nature Reviews Microbiology 2005, 3:557-565.
95. Hu J.-D., Tang H.-Q., Zhang Q., Fan J., Hong J., Gu J.-Z., Chen J.-L. Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. World Journal of Gastroenterology 2011, 17:727-734.
96. Benson D.A., Karsch-Mizrachii I., Clark K., Lipman D.J., Ostell J., Sayers E.W. GenBank. Nucleic Acids Research 2012, 40:D48-D53.
97. Armitage E.G., Kotze H.L., Lockyer N.P. Imaging of metabolites using secondary ion mass spectrometry. Metabolomics 2012, 9:102-109.
98. Fletcher J.S., Kotze H.L., Armitage E.G., Lockyer N.P., Vickerman J.C. Evaluating the challenges associated with time-of-fight secondary ion mass spectrometry for metabolomics using pure and mixed metabolites. Metabolomics 2013, 9:535-544.
99. Armitage E.G., Kotze H.L., Fletcher J.S., Henderson A., Williams K.J., Lockyer N.P., Vickerman J.C. Time-of-flight SIMS as a novel approach to unlocking the hypoxic properties of cancer. Surface and Interface Analysis 2013, 45:282-285.
100. Kotze H.L., Armitage E.G., Fletcher J.S., Henderson A., Williams K.J., Lockyer N.P., Vickerman J.C. ToF-SIMS as a tool for metabolic profiling small biomolecules in cancer systems. Surface and Interface Analysis 2013, 45:277-281.